# Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation

> **NCT03162120** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Elpen Pharmaceutical Co. Inc.**

## Conditions studied

- Atrial Fibrillation
- Recurrence

## Interventions

- **DRUG:** Ranolazine plus Metoprolol Combination
- **DRUG:** FlecainidE pluS Metoprolol Combination

## Key facts

- **NCT ID:** NCT03162120
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)
- **Last updated:** 2019-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162120, "Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03162120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*